MSC-Derived Extracellular Vesicles
Idiopathic Pulmonary Fibrosis · EV cargo (miR-29, let-7d) delivers anti-fibrotic miRNA without cell engraftment risk
Mechanism
EV cargo (miR-29, let-7d) delivers anti-fibrotic miRNA without cell engraftment risk
Development stage
Phase I
Evidence level
Level 3 (Phase I)
Developer
Multiple
Overview
miR-29 depleted in IPF lung. EVs from young MSCs reduce fibrosis markers. Better safety than cell therapy.
Explore related
Medical disclaimer. This page summarizes research about MSC-Derived Extracellular Vesicles for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.